Island Pharmaceuticals Limited (ASX:ILA)
Australia · Delayed Price · Currency is AUD 0.4200
+0.0450 (12.00%)
Jan 30, 2026, 3:49 PM AEST
Island Pharmaceuticals Company Description
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.
Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases.
Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Island Pharmaceuticals Limited
| Country | Australia |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Foster |
Contact Details
Address: 117 Camberwell Road Hawthorn East, VIC 3123 Australia | |
| Phone | 61 3 7036 7675 |
| Website | islandpharmaceuticals.com |
Stock Details
| Ticker Symbol | ILA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000138869 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. | MD, Chief Executive Officer, President and Executive Director |
| Cameron Peter Jones C.A. | Chief Financial Officer and Company Secretary |